方法：回顾分析临床确诊为病理性近视CNV患者24例25眼，所有患者行ETDRS视力表检查、前置镜下眼底检查、荧光素眼底血管造影(FFA)、吲哚菁绿血管造影(ICGA)、光学相干断层扫描(OCT)检查。所有患者按照常规内眼手术操作要求玻璃体腔内注射10mg/mL雷珠单抗0.05mL，随访4～10mo。观察比较治疗前后最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)。

结果：所有患者均未出现与治疗相关的局部和全身并发症。平均治疗次数为1.52次。治疗前最佳矫正视力(BCVA)平均23.93±12.46个字母； 末次随访BCVA平均40.63±7.25个字母，较治疗前提高14.27±9.36个字母，差异有统计学意义(t=5.74，P<0.05)。治疗前CMT平均363.47±119.62μm，末次随访平均CMT为190.31±37.02μm，较治疗前下降72.82±60.57μm，差异有统计学意义(t=3.96，P<0.05)。

结论：玻璃体腔注射雷珠单抗治疗病理性近视CNV是安全有效的，有利于提高患者视力，减轻视网膜水肿，停止或减少病灶的渗漏。

METHODS:In this retrospective and comparative study,24 patients(25 eyes)with CNV secondary to pathologic myopia were enrolled. All patients were assessed by examinations of ETDRS visual acuity chart, preplaced-mirror ophthalmoscopy, fundus fluorescein angiography(FFA), indocyanine green angiography(ICGA)and optical coherence tomography(OCT). Patiens received intravitreally injected ranibizumab 0.5mg(0.05mL). Treatments were repeated if the follow-up indicated that it was necessary. The follow-up periods were 4～10mo. Best corrected visual acuity(BCVA), central macular thickness(CMT)and leakage of CNV before and after the treatment were compared.

RESULTS:No local or systemic complications occurred in any patients during the treatment or follow-up. The average time of injection was 1.52. The mean BCVA was 23.93±12.46 letters before the therapy. In the last follow-up, the mean BCVA was 40.63±7.25 letters, improved by 14.27±9.36 letters and the difference was statically significant(t=5.74, P<0.05). The mean CMT was 363.47±119.62μm before treatments and 190.31±37.02μm after treatments which was 72.82±60.57 μm less than the pre-treatment values and the difference was statically significant(t=3.96, P<0.05).

CONCLUSION:Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective, and this treatment can improve visual acuity, reduce retina edema and leakage of CNV.